Abstract
The mevalonate pathway produces isopentenyl diphosphate (IPP), a building block for polyisoprenoid synthesis, and is a crucial pathway for growth of the human bacterial pathogen Enterococcus faecalis The final enzyme in this pathway, mevalonate diphosphate decarboxylase (MDD), acts on mevalonate diphosphate (MVAPP) to produce IPP while consuming ATP. This essential enzyme has been suggested as a therapeutic target for the treatment of drug-resistant bacterial infections. Here, we report functional and structural studies on the mevalonate diphosphate decarboxylase from E. faecalis (MDDEF). The MDDEF crystal structure in complex with ATP (MDDEF-ATP) revealed that the phosphate-binding loop (amino acids 97-105) is not involved in ATP binding and that the phosphate tail of ATP in this structure is in an outward-facing position pointing away from the active site. This suggested that binding of MDDEF to MVAPP is necessary to guide ATP into a catalytically favorable position. Enzymology experiments show that the MDDEF performs a sequential ordered bi-substrate reaction with MVAPP as the first substrate, consistent with the isothermal titration calorimetry (ITC) experiments. On the basis of ITC results, we propose that this initial prerequisite binding of MVAPP enhances ATP binding. In summary, our findings reveal a substrate-induced substrate-binding event that occurs during the MDDEF-catalyzed reaction. The disengagement of the phosphate-binding loop concomitant with the alternative ATP-binding configuration may provide the structural basis for antimicrobial design against these pathogenic enterococci.
Highlights
The mevalonate pathway produces isopentenyl diphosphate (IPP), a building block for polyisoprenoid synthesis, and is a crucial pathway for growth of the human bacterial pathogen Enterococcus faecalis
Enzymology experiments show that the MDDEF performs a sequential ordered bi-substrate reaction with mevalonate diphosphate (MVAPP) as the first substrate, consistent with the isothermal titration calorimetry (ITC) experiments
The substrate-binding mechanism of mevalonate diphosphate decarboxylase (MDD) from chickens was determined to belong to a sequential bi-substrate mechanism with MVAPP as the first substrate [28]; from our study, we determined prokaryotic MDD from E. faecalis binds MVAPP first during the enzymatic reaction
Summary
The mevalonate pathway produces isopentenyl diphosphate (IPP), a building block for polyisoprenoid synthesis, and is a crucial pathway for growth of the human bacterial pathogen Enterococcus faecalis. The final enzyme in this pathway, mevalonate diphosphate decarboxylase (MDD), acts on mevalonate diphosphate (MVAPP) to produce IPP while consuming ATP This essential enzyme has been suggested as a therapeutic target for the treatment of drug-resistant bacterial infections. From the Centers for Disease Control and Prevention reports the deaths and the cost resulting from infectious diseases and emphasizes the urgency to control drug-resistant bacteria [2]. This critical list includes vancomycin-resistant enterococci (VRE), which cause a range of enterococcal infections such as bacteremia, urinary tract infections, intra-abdominal and pelvic infections, central nervous system infections, skin and skin structure infections, and infective enterocarditis [2,3,4]. For the protection of patients in health care settings, new approaches and new antimicrobial agents against enterococcal infections are urgently needed
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.